Annalisa Guida

1.2k total citations
39 papers, 323 citations indexed

About

Annalisa Guida is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Annalisa Guida has authored 39 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 24 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Annalisa Guida's work include Renal cell carcinoma treatment (22 papers), Renal and related cancers (11 papers) and Cancer Diagnosis and Treatment (8 papers). Annalisa Guida is often cited by papers focused on Renal cell carcinoma treatment (22 papers), Renal and related cancers (11 papers) and Cancer Diagnosis and Treatment (8 papers). Annalisa Guida collaborates with scholars based in Italy, France and United States. Annalisa Guida's co-authors include Laurence Albigès, Bernard Escudier, Émeline Colomba, Lisa Derosa, Yohann Loriot, Karim Fizazi, G. Baciarello, Fiorella Ruatta, Ronan Flippot and Roberto Sabbatini and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Annalisa Guida

34 papers receiving 319 citations

Peers

Annalisa Guida

PRM

ONCOL

SURGE

María José Méndez-Vidal Spain

Chukwuemeka Ikpeazu United States

Giulia Grizzi Italy

Alketa Hamzaj Italy

Niels Viggo Jensen Denmark

Darren M. Kocs United States

Katharine Cuff Australia

Sufia Safina Russia

Daniela Cullurà Italy

Nathalie Syz France

María José Méndez-Vidal Spain

Annalisa Guida

252 ×1.0

PRM

147 ×0.9

ONCOL

139 ×1.3

110 ×1.5

142 ×2.3

SURGE

Citations per year, relative to Annalisa Guida Annalisa Guida (= 1×) peers María José Méndez-Vidal

Countries citing papers authored by Annalisa Guida

Since Specialization

Citations

This map shows the geographic impact of Annalisa Guida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annalisa Guida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annalisa Guida more than expected).

Fields of papers citing papers by Annalisa Guida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annalisa Guida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annalisa Guida. The network helps show where Annalisa Guida may publish in the future.

Co-authorship network of co-authors of Annalisa Guida

This figure shows the co-authorship network connecting the top 25 collaborators of Annalisa Guida. A scholar is included among the top collaborators of Annalisa Guida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annalisa Guida. Annalisa Guida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gili, Alessio, Annalisa Guida, Fabio Arcidiacono, et al.. (2025). Fast-Track Diagnostic Pathway for Lung Cancer Detection: Single-Center Experience. Journal of Clinical Medicine. 14(9). 2915–2915.

Guida, Annalisa, Alessio Gili, Claudia Mosillo, et al.. (2024). Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI Study. Clinical Genitourinary Cancer. 22(6). 102225–102225.

Guida, Annalisa, et al.. (2024). The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer. Cancer Treatment Reviews. 128. 102766–102766.

Colomba, Émeline, Carolina Alves Costa Silva, Gwénaël Le Teuff, et al.. (2022). Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. Journal of Cachexia Sarcopenia and Muscle. 13(5). 2405–2416. 8 indexed citations

Guida, Annalisa, Francesco Facchinetti, Giovanni M. Marchetti, et al.. (2022). Ad Hoc Afatinib in an Eldery Lung Cancer Patient with EGFR Exon 19 Deletion L747-A750>P. Advances in respiratory medicine. 90(3). 234–235. 1 indexed citations

Cortellini, Alessio, Elisa Roldán, Margarita García, et al.. (2021). 1560O Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection. Annals of Oncology. 32. S1130–S1130. 3 indexed citations

Cerbone, Luigi, Vincenzo Di Nunno, Carolina Alves Costa Silva, et al.. (2021). Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 20(1). 80–87. 6 indexed citations

Guida, Annalisa, Roberto Sabbatini, Lara Gibellini, et al.. (2021). Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. Cancer Treatment Reviews. 94. 102157–102157. 17 indexed citations

Cortesi, Laura, Federica Domati, Annalisa Guida, et al.. (2021). <i>BRCA</i> mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees. Cancer Biology and Medicine. 18(2). 470–476. 5 indexed citations

10.

Ratta, Raffaele, Annalisa Guida, Florian Scotté, et al.. (2020). PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer and Prostatic Diseases. 23(4). 549–560. 30 indexed citations

11.

Massari, Francesco, Vincenzo Di Nunno, Annalisa Guida, et al.. (2020). Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clinical Genitourinary Cancer. 19(1). 32–40. 21 indexed citations

12.

Cerbone, Luigi, Vincenzo Di Nunno, Ronan Flippot, et al.. (2020). 743P Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC). Annals of Oncology. 31. S577–S577. 1 indexed citations

13.

Colomba, Émeline, Gwénaël Le Teuff, Annalisa Guida, et al.. (2019). Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC). Annals of Oncology. 30. v390–v391. 2 indexed citations

14.

Masini, Cristina, Maria Giuseppa Vitale, Marco Maruzzo, et al.. (2018). Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. Clinical Genitourinary Cancer. 17(1). e150–e155. 6 indexed citations

15.

Guida, Annalisa, Laurence Albigès, Lisa Derosa, et al.. (2017). Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. Clinical Genitourinary Cancer. 15(6). e1081–e1088. 4 indexed citations

16.

Giorgi, Ugo De, Giuseppe Procopio, Annalisa Guida, et al.. (2017). Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP). Annals of Oncology. 28. v320–v321. 3 indexed citations

17.

Passalacqua, Rodolfo, Silvia Lazzarelli, Maddalena Donini, et al.. (2017). Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014). BMC Cancer. 17(1). 493–493. 4 indexed citations

18.

Matias, Margarida, Gwénaël Le Teuff, Laurence Albigès, et al.. (2017). Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. European Journal of Cancer. 79. 185–192. 24 indexed citations

19.

Derosa, Lisa, Gwénaël Le Teuff, Brice Chanez, et al.. (2016). Brain and pancreatic metastases: A clinico-pathological comparison of various facets of tumor heterogeneity in renal cell carcinoma - The BRAVE project. Annals of Oncology. 27. vi287–vi287. 1 indexed citations

20.

Derosa, Lisa, Annalisa Guida, Laurence Albigès, et al.. (2015). New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC). Annals of Oncology. 26. vi53–vi53. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact